The iPATH trial, spearheaded by Sara Singer of Stanford University, is focused on improving diabetes care for underserved populations, particularly in federally qualified health centers (FQHCs) across California, Massachusetts, Ohio, and Puerto Rico.
Funded by the National Institute on Minority Health and Health Disparities, this five-year study aims to implement innovative, patient-centered care strategies for adults with type 2 diabetes. The project includes a comparative analysis in 12 FQHCs to ascertain their current treatment methods before moving forward with a modularized intervention in eight of these centers.
Singer emphasizes the unique challenges posed by the trial’s multisite nature, including recruiting participants and managing complex agreements across various teams. To tackle these, the team has prioritized communication and collaboration, allowing them to remain on track despite initial setbacks.
The ultimate goal of the iPATH trial is to generate actionable insights that not only enhance diabetes care in FQHCs but also contribute to reducing health disparities faced by racial and ethnic minorities.
By providing evidence-based interventions, the initiative hopes to enable these centers to meet incentive goals and improve overall patient outcomes. Singer reflects on the collaborative support received from the NIH Pragmatic Trials Collaboratory, highlighting how it has shaped the project’s methodological framework.
See “iPATH Trial Aims to Improve Diabetes Care in Community Health Centers” (August 26, 2024)
